MISGAV, Israel & LONDON--(BUSINESS WIRE)--Medgenics (AIM:MEDG), the US-incorporated biopharmaceutical company, is pleased to announce that it has appointed Dr. Ehud Shoshani, former CEO of Quintiles, Israel, as its Vice President of Clinical Affairs. Dr. Shoshani will manage the Company’s Phase I/II clinical trials with EPODURE, its lead sustained-action protein therapy to treat anaemia, which is scheduled to start mid-2008 pending approval by the Israel Ministry of Health (MoH).
